
NASDAQHealthcareMedical - Instruments & Supplies
أحدث البيانات المتاحة
1.345 US$
−0.09 US$ · -6.27%
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
الإغلاق السابق
1.345 US$
−0.09 US$ · -6.27%
قبل افتتاح السوق
1.35 US$
+0.005 US$ · +0.37%
13 أكتوبر، 5:18 ص ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
نطاق اليوم
السعر الحالي 1.345 US$
نطاق 52 أسبوعًا
السعر الحالي 1.345 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
45
قيمة عادلة
المشاعر
38
هبوطي
المخاطر
66
مخاطر مرتفعة
الزخم
39
زخم متراجع
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
نطاق اليوم
السعر الحالي 1.345 US$
نطاق 52 أسبوعًا
السعر الحالي 1.345 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 28.51 مليون USD | 30.78 مليون USD | 36.12 مليون USD | 27.8 مليون USD | 17.98 مليون USD |
| تكلفة البضاعة المباعة | 22.25 مليون USD | 30.4 مليون USD | 26.55 مليون USD | 21.86 مليون USD | 14.11 مليون USD |
| الربح الإجمالي | 6.26 مليون USD | 380 ألف USD | 9.57 مليون USD | 5.95 مليون USD | 3.87 مليون USD |
| البحث والتطوير | 11.37 مليون USD | 24.8 مليون USD | 54.03 مليون USD | 49.05 مليون USD | 22.49 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 28.22 مليون USD | 51.86 مليون USD | 94.96 مليون USD | 88.6 مليون USD | 58.49 مليون USD |
| نفقات التشغيل | 39.6 مليون USD | 104.36 مليون USD | 224.81 مليون USD | 137.64 مليون USD | 80.98 مليون USD |
| دخل الفوائد | 1.11 مليون USD | 2.1 مليون USD | 3.31 مليون USD | 1.51 مليون USD | 236 ألف USD |
| مصاريف الفوائد | 298 ألف USD | 289 ألف USD | 5.12 مليون USD | 298 ألف USD | 927 ألف USD |
| الاستهلاك والإطفاء | 9.73 مليون USD | 14.23 مليون USD | 13.71 مليون USD | 9.62 مليون USD | 3.37 مليون USD |
| الدخل التشغيلي | −33.34 مليون USD | −103.98 مليون USD | −215.25 مليون USD | −131.7 مليون USD | −77.1 مليون USD |
| صافي الدخل | −26.4 مليون USD | −112.02 مليون USD | −232.49 مليون USD | −132.6 مليون USD | −72.44 مليون USD |
تم تحديث حقائق الشركة 13 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
46.50 US$
ارتفاع محتمل بنسبة 3357.25%| الإجراء | تاريخ النفاذ | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
تقسيم الأسهم | 27 يناير 2025 | 1:60 | — | — |
تقسيم الأسهم | 7 أغسطس 2023 | 1:10 | — | — |
ساري 27 يناير 2025
1:60
ساري 7 أغسطس 2023
1:10
صناديق متداولة تفصح عن تعرضها لهذا السهم.
المحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.